Towards 2000—New Strategies for Acute Coronary Syndromes (II)
Plaque Disruption
Coronary Artery Disease
The Role of Enzymatic Markers in the New Millennium
St Segment Monitoring in Patients with Acute Ischemic Syndromes
Thrombolytic or Angioplasty Therapy of Evolving Myocardial Infarction?
New Thrombolytics
The Thrombin Hypothesis
Antiplatelet Therapy in Coronary Disease
New Agents, New Trials, New Solutions
Health Economics of Acute Coronary Syndromes
Use and Impact of Registries for Myocardial Infarction on Process of Care and Outcomes
Similarity in Presentation and Response to Thrombolysis Among Women and Men with Pulmonary Embolism
The Open Artery Hypothesis
Identification of a BamHI Polymorphism for the Urokinase Gene Associated with Symptomatic Coronary Artery Disease
Interleukin-4 Modulation of Platelet-Derived Growth Factor–Induced Smooth Muscle Cell Urokinase Plasminogen Activator
Phosphorothioate Oligodeoxynucleotide Inhibition of Restenosis
Human Plasma Fibronectin Mediates Adhesion of U937 Cells by RGD and CS1
The Antioxidant, N-(2-mercaptopropionyl)-glycine (MPG), Does Not Reduce Myocardial Infarct Size in an Acute Canine Model of Myocardial Ischemia and Reperfusion
Gene Polymorphisms for PAI-1 Are Associated with the Angiographic Extent of Coronary Artery Disease
Impact of a Simple Inexpensive Quality Assurance Effort on Physician's Choice of Thrombolytic Agents and Door-to-Needle Time
Angiographic Morphology Following Heparin and Aspirin Therapy in Patients with Acute Coronary Syndromes and Intracoronary Thrombus
Effect of a Change in the Sleep/Wake Cycle on the Diurnal Variation of Fibrinolytic Parameters
Lack of Correlation Between Activation of Hemostatic Mechanism and Inflammation in Unstable Angina Pectoris